Pfizer Inc.: Is Its $13 Billion M&A Budget & Product Pipeline Enough To Stay Ahead Of Rival Large Pharma? 

Pfizer’s Q2 2025 financial results reflect a blend of strategic execution and a challenging external milieu. The company reported revenues of $14.7 billion, marking a 10% operational increase year-over-year, driven by robust growth across the U.S. and international divisions. Key contributors to this growth included products like the Vyndaqel family, Comirnaty, and Paxlovid, alongside others such as Eliquis and Padcev. These gains were partially offset by declining revenues from Ibrance and an $825 million impact due to increased manufacturer discounts from the IRA Medicare Part D redesign.